ABVC BioPharma receives Nasdaq deficiency notice for bid price below $1.00

ABVC BIOPHARMA, INC.

Received Nasdaq notice on July 10, 2024 for non-compliance with minimum $1.00 bid price rule over 30 consecutive days.
Compliance deadline is January 6, 2025; can regain if bid price closes at $1.00+ for 10 business days.
If not cured, may qualify for additional 180-day period if other initial listing standards are met.
Company may consider a reverse stock split to cure the deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.